Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development

Antimicrobial Agents and Chemotherapy
Eric NuermbergerDebra Hanna

Abstract

Novel tuberculosis (TB) drug regimens are urgently needed, and their development will be enabled by improved preclinical approaches that more effectively inform and ensure safe selection of clinical candidates and drug combination/regimens. An evidence-based approach for the assessment of nonclinical models supporting TB drug development has been proposed by a joint partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the Critical Path to TB Drug Regimens (CPTR) Consortium.

References

Oct 31, 2009·American Journal of Respiratory and Critical Care Medicine·Galina V MukamolovaMichael R Barer
Feb 4, 2010·The Journal of Antimicrobial Chemotherapy·Zahoor AhmadPetros C Karakousis
May 29, 2012·The Journal of Antimicrobial Chemotherapy·Andrea ZelmerUlrich E Schaible
Feb 4, 2014·Nature Reviews. Microbiology·Véronique Dartois
May 27, 2015·The Journal of Infectious Diseases·Tawanda GumboEric Nuermberger
Jun 4, 2015·Disease Models & Mechanisms·Jean-Philippe LanoixEric L Nuermberger
Aug 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jotam G PasipanodyaTawanda Gumbo
Aug 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Tawanda GumboDebra Hanna
Aug 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Tawanda GumboEric Nuermberger

❮ Previous
Next ❯

Citations

May 22, 2016·Infectious Disease Clinics of North America·Sebastian G KurzCharles M Bark
Jun 9, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christian LienhardtChristine F Sizemore
Oct 30, 2016·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Debra HannaMarco Schito
Jul 26, 2017·Antimicrobial Agents and Chemotherapy·Bas C MourikJurriaan E M de Steenwinkel
Dec 22, 2019·Journal of Bioethical Inquiry·Bridget Pratt
Jan 4, 2020·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Hao ChenXiaohui Huang
Apr 11, 2018·Scientific Reports·Bas C MourikJurriaan E M de Steenwinkel
Mar 6, 2019·Frontiers in Pharmacology·Lloyd TannerLubbe Wiesner
Apr 2, 2020·Antimicrobial Agents and Chemotherapy·Norimitsu HariguchiMakoto Matsumoto
Jun 3, 2017·ILAR Journal·Judith A HewittShai D Silberberg
Aug 19, 2020·Annual Review of Pharmacology and Toxicology·Jacqueline P ErnestRada M Savic
Feb 9, 2021·Clinical Pharmacology and Therapeutics·Craig R RaynerKaren Rowland-Yeo
Jun 24, 2017·Microbiology Spectrum·Eric L Nuermberger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.